

Laura Cosmai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6928819/publications.pdf>

Version: 2024-02-01

55
papers

1,024
citations

430874

18
h-index

454955

30
g-index

57
all docs

57
docs citations

57
times ranked

1449
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015, 11, 354-370.	9.6	95
2	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. <i>Nature Reviews Nephrology</i> , 2019, 15, 423-433.	9.6	68
3	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1329-1338.	2.4	64
4	Onco-nephrology: a decalogue: Table 1. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 515-519.	0.7	63
5	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	5.2	47
6	Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2013-2019.	0.7	46
7	Glomerular diseases and cancer: evaluation of underlying malignancy. <i>Journal of Nephrology</i> , 2016, 29, 143-152.	2.0	45
8	Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 38-50.	2.4	39
9	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012, 110, 692-698.	2.5	39
10	Renal cancer in kidney transplanted patients. <i>Journal of Nephrology</i> , 2015, 28, 659-668.	2.0	38
11	Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). <i>Journal of Nephrology</i> , 2017, 30, 171-180.	2.0	38
12	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 631-643.	2.0	38
13	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. <i>Targeted Oncology</i> , 2018, 13, 705-714.	3.6	35
14	Renal toxicity of anticancer agents targeting HER2 and EGFR. <i>Journal of Nephrology</i> , 2015, 28, 647-657.	2.0	33
15	Opening an onconephrology clinic: recommendations and basic requirements. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1503-1510.	0.7	31
16	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	1.9	30
17	Preventive strategies for acute kidney injury in cancer patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 70-83.	2.9	28
18	Lenvatinib-induced renal failure: two first-time case reports and review of literature. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 379-385.	3.3	27

#	ARTICLE	IF	CITATIONS
19	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	5.2	26
20	Acute Kidney Injury in Cancer Patients. <i>Contributions To Nephrology</i> , 2018, 193, 137-148.	1.1	18
21	Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report. <i>American Journal of Kidney Diseases</i> , 2008, 52, 137-139.	1.9	16
22	Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. <i>Journal of Nephrology</i> , 2019, 32, 57-64.	2.0	16
23	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 39-51.	4.4	11
24	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015, 11, 3159-3166.	2.4	10
25	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019, 105, 3-12.	1.1	10
26	Transplantation of kidneys with tumors. <i>Journal of Nephrology</i> , 2016, 29, 163-168.	2.0	9
27	Introduction to the Journal of Onco-Nephrology. <i>Journal of Onco-Nephrology</i> , 2017, 1, 1-4.	0.6	9
28	Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e150-e155.	1.9	9
29	Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. <i>ESMO Open</i> , 2020, 5, e000618.	4.5	9
30	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020, 98, 1407-1418.	5.2	8
31	Exploring the Spectrum of Kidney Ciliopathies. <i>Diagnostics</i> , 2020, 10, 1099.	2.6	8
32	Vitamin K and Kidney Transplantation. <i>Nutrients</i> , 2020, 12, 2717.	4.1	6
33	Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients. <i>Current Vascular Pharmacology</i> , 2018, 16, 603-609.	1.7	6
34	Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors. <i>Cancer Management and Research</i> , 2021, Volume 13, 7623-7636.	1.9	6
35	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. <i>Nutrients</i> , 2021, 13, 3567.	4.1	6
36	Treatment of acute kidney injury in cancer patients. CKJ: <i>Clinical Kidney Journal</i> , 2022, 15, 873-884.	2.9	6

#	ARTICLE	IF	CITATIONS
37	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 2429-2430.	1.6	5
38	Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 581-589.	2.3	5
39	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. <i>Current Opinion in Urology</i> , 2021, 31, 236-241.	1.8	4
40	Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference. <i>Transplantation Reviews</i> , 2021, 35, 100636.	2.9	4
41	Urothelial cancer: Once there were urologists, now oncologists joined, what about nephrologists?. <i>Journal of Onco-Nephrology</i> , 2018, 2, 3-5.	0.6	3
42	The basics of onco-nephrology in the renal clinic. <i>Journal of Nephrology</i> , 2020, 33, 1143-1149.	2.0	3
43	Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 2361-2370.	2.8	2
44	Acute Kidney Injury in Oncology and Tumor Lysis Syndrome. , 2019, , 234-250.e1.		1
45	How to use dialysis wisely in cancer patients?. <i>Journal of Onco-Nephrology</i> , 2021, 5, 79-86.	0.6	1
46	Risk of acute kidney injury in cancer patients after iodinated contrast medium administration and prophylactic strategies: Summary from the most recent guidelines. <i>Journal of Onco-Nephrology</i> , 2021, 5, 114-119.	0.6	1
47	Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?. <i>Annals of Translational Medicine</i> , 2019, 7, S15-S15.	1.7	1
48	Editorial Comment from Dr Porta <i>et al</i> . to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the <sc>USA</sc>. <i>International Journal of Urology</i> , 2017, 24, 279-280.	1.0	0
49	CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure. <i>Annals of Oncology</i> , 2017, 28, vi17.	1.2	0
50	P1558THE "HOME JAIL HEMODIALYSIS" PROJECT IN MILAN, ITALY: AN UNIQUE EXPERIENCE ABLE TO SAVE MONEY AND IMPROVE SECURITY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
51	Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors. , 2020, , 299-306.e1.		0
52	Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies. , 2015, , 555-575.		0
53	The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16063-e16063.	1.6	0
54	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 572-572.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Nephrological management of renal cell carcinoma (RCC) patients: A narrative review. Journal of Onco-Nephrology, 0, , 239936932210984.	0.6	0